Total for the last 12 months
number of access : ?
number of downloads : ?
ID 116113
Author
Bando, Hiroshi Tokushima University|Japan Low Carbohydrate Diet Promotion Association|Sakamoto Hospital KAKEN Search Researchers
Iwatsuki, Noboru Sakamoto Hospital
Tanaka, Hisashi Higashikagawa city council
Sakamoto, Kazuki Sakamoto Hospital
Ogawa, Tomoya Sakamoto Hospital
Keywords
Xultophy
Degludec and liraglutide (IDegLira)
Glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA)
DUAL (Dual Action of Liraglutide and Insulin Degludec)
European Xultophy Treatment Retrospective Audit (EXTRA)
Content Type
Journal Article
Description
The case is a 65-year-old male who has been treated for Type 2 diabetes mellitus (T2DM) for 26 years. He has no previous history of cerebral vascular accident (CVA) or coronary heart disease (CHD). He has been treated on insulin therapy, and recently his glucose variability became worse due to the irregular lifestyle. Then, diabetic treatment was changed to Xultophy, which consists of insulin degludec and liraglutide. Providing 16 units of Xultophy brought him a satisfactory daily profile of blood glucose, which seemed to be lower doses compared with the ordinary standard amount. Treatment of Xultophy seems to be effective and some discussion would be described from several points of view.
Journal Title
Biomedical Science Journal
Publisher
Ciencia Scientific Publisher
Volume
2
Issue
1
Start Page
BSJ-21-17
Published Date
2021-03-24
Rights
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license(https://creativecommons.org/licenses/by/4.0/).
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences